Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1674-1681

  Morris, C ^a   Iacobelli, S ^a   Brand, R ^a   Bjorkstrand, D ^a   Drake, M ^a   Niedenwieser, D ^a   Gahrton, G ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD AUTOTRANSFUSION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; HUMAN; METHODOLOGY; MORTALITY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TIME; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; REGISTER; RETROSPECTIVE STUDY; STATISTICS; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 2442649309     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.144     Document Type: Article

References (22)

1. Altal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
2. Barlogie B, Jagannath S. Vesole D, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789-793, 1997
3. Lenhoff S, Hjorth M, Holmberg E, et al: Impact on survival of high dose therapy with autologous stem cell supporting patients younger than 60 years with newly diagnosed multiple myeloma: A population based study. Blood 95:7-11, 2000
4. Harousseau JL, Altal M: The role of stem cell transplantation in multiple myeloma. Blood Rev 16:245-253, 2002
5. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
6. Tricot G, Jagannath S, Vesole DH, et al: Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy. Bone Marrow Transplantation 16:7-11, 1995
7. Mehta J, Tricot G, Jagannath S, et al: Salvage autologous or allogenic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft. Bone Marrow Transplantation 21:887-892, 1998
8. Kulkarni S, Powles R, Singhal S, et al: Second autografts for relapsed multiple myeloma: Is tandem autotransplantation better? Clinical care: recurrence, secondary neoplasia and late complications after transplantation. Blood 92:344b, 1998(suppl 1)
9. Bjorkstrand B: European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Sem Haematol 38:219-225, 2001
10. Keading JP, Klein JP, Horowitz HM: Multi state models and outcome prediction in bone marrow transplantation. Stat Med 20:1870-1885, 2000
11. Hougard P: Fraility models for survival data. Lifetime Data Anal 1:255-273, 1995
12. Cavo M, Tosi P, Zamagni E, et al: The Bologna 96 clinical trial of single vs. double autotransplants for previously untreated multiple myeloma patients. Blood 100:179a, 2003
13. Moreau P, Misbahi R, Milpied N, et al: Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia 16:1838-1843, 2002
14. Desikan R, Barlogie B, Sawyer J, et al: Results of high dose therapy for 1000 patients with multiple myeloma: Durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008-4010, 2000
15. Segren CM, Sonnereld P, van der Holt B, et al: Overall and event-free survived are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomised phase 3 study. Blood 101:2144-2151, 2003
16. Fermand J-P, Alberti C, Marolleau J-P: Single versus tandem high dose therapy (HOT) supported with autologous blood stem cell (ABSC) transplantation using unselected of CD34 enriched ABSC: Results of a two by two designed randomised trial in 230 young patients with multiple myeloma (MM). Haematol J 4:59, 2003 (supp 1)
17. Seong C, Delasalle K, Hayes K, et al: Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101:189-194, 1998
18. Sirohi B, Powles R, Singhal S, et al: Second high-dose melphalan autograft for myeloma patients relapsing after one autograft: Results equivalent to tandem transplantation. Bone Marrow Transplantation 29:S12, 2002 (suppl 2)
19. Fermand JP, Ravaud P, Chevret S, et al: High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131-3136, 1998
20. Gertz MA, Lacy MQ, Inwards DJ, et al: Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplantation 26:45-50, 2000
21. Hideshima T, Chauhan D, Podar K, et al: Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 28:607-612, 2001
22. Morris TCM, Ranaghan E, Ogilvie C, et al: Population-based study of the 'young' myeloma population: Only a minority of potentially eligible patients with myeloma receive stem cell transplantation; a study of the contributing factors. Haematol J 4:203, 2003 (suppl 1)